TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 72 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Study: 31277301
Drug: GEE extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEE extract 1000 mg/day
Study: 27753794
Drug: Hepavax-Gene TF
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hepavax-Gene TF vaccine
Study: 23585310
Drug: No Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Test Atorvastatin 80 mg/day (A80)
Study: 23585310
Drug: No Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Test Pravastatin 40 mg/day (P40)
Study: 22569014
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Study: 22569014
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Study: 19019052
Drug: Conventional expectant
Normalized name: docosahexaenoic acid Oral Capsule [Expecta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional expectant therapy (adequate hydration, complete bed rest, and analgesics)
Study: 17710964
Drug: Pueraria mirifica,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica, oral 50 and 100 mg capsule, once daily for six months
Study: 9041281
Drug: Thyrotropin-Releasing Hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-Releasing Hormone (TRH) 200 microg
Study: 8261468
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg furafylline
Study: 29890724
Drug: Fructose 5
Normalized name: fructose 5 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose 5 g
Study: 29890724
Drug: Fructose 10
Normalized name: fructose 10 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose 10 g
Study: 29797503
Drug: Allulose 5
Normalized name: Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allulose 5 g
Study: 29797503
Drug: Allulose 10
Normalized name: Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allulose 10 g
Study: 29890724
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g)
Study: 19589122
Drug: Manidipine 20
Normalized name: manidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 20 mg
Study: 12046885
Drug: Compound ablation
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound ablation (Group 1)
Study: 31532805
Drug: Insight, medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight, medication adherence, addiction
Study: 27993816
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg/week for 1 year)
Study: 21276883
Drug: LPV/r (lopinavir/ritonavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r (lopinavir/ritonavir) monotherapy
Study: 19144144
Drug: Overall prevalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prevalence of CSP-antibodies during dry season
Study: 19144144
Drug: Overall prevalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prevalence of CSP-antibodies during rainy season
Study: 15491083
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily mouthrinsing with 0.2% sodium fluoride (phase 2)
Study: 15491083
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily mouthrinsing with 0.03% triclosan and 0.05% sodium fluoride (phase 3)
Study: 15491083
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily mouthrinsing with 0.2% chlorhexidine (phase 4)
Study: 9762666
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor V beta 5 analysis in MS patients (8 patients)
Study: 9762666
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor V beta 17 analysis in MS patients (8 patients)
Study: 7816001
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g elemental calcium/day (n = 9)
Study: 28586588
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of bupivacaine plus methylprednisolone
Study: 28586588
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of bupivacaine only
Study: 9505748
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + lignocaine 0.1 mg.kg‐1
Study: 9505748
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + lignocaine 0.2 mg.kg‐1
Study: 3292250
Drug: Taurine-supplemented formula
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine-supplemented formula (480 mumol/l)
Study: 25386668
Drug: Oral CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CoQ10 (200 mg/day) plus NADH (20 mg/day) supplementation
Study: 21395643
Drug: Hydrofluoroalkane formulation
Normalized name: HYDROFLUOROALKANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrofluoroalkane formulation of budesonide (800 µg twice daily)
Study: 21395643
Drug: Chlorofluorocarbon formulation
Normalized name: Chlorofluorocarbon 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorofluorocarbon formulation of budesonide (800 µg twice daily)
Study: 21395643
Drug: Hydrofluoroalkane formulation
Normalized name: HYDROFLUOROALKANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrofluoroalkane formulation of budesonide (200 µg followed by 800 µg for 4 weeks)
Study: 21395643
Drug: Chlorofluorocarbon formulation
Normalized name: Chlorofluorocarbon 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorofluorocarbon formulation of budesonide (200 µg followed by 800 µg for 4 weeks)
Study: 18693327
Drug: Per cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per cycle analysis of treatment
Study: 10852601
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) in combination with cyclosporine (CsA) and prednisone (Pred)
Study: 9085014
Drug: Bronchial hyperresponsiveness
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial hyperresponsiveness defined as the provocative dose causing a 20% fall in FEV1
Study: 9085014
Drug: Bronchial hyperresponsiveness
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial hyperresponsiveness defined using corresponding cut‐off values of the linear dose‐response slopes of the percent decline in FEV1 (DRS)
Study: 25970741
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention or metformin
Study: 22678095
Drug: GentleYAG (low-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GentleYAG (low-energy Nd:YAG laser treatment without opening the lens capsule)
Study: 18783071
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate ointment
Study: 15087961
Drug: Morphine patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient‐controlled analgesia with presurgical bupivacaine sciatic nerve blockade
Study: 15087961
Drug: Morphine patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient‐controlled analgesia with postsurgical bupivacaine sciatic nerve blockade
Study: 15087961
Drug: Morphine patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient‐controlled analgesia alone
Study: 8418020
Drug: maxEPA 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: maxEPA 20 g/day
Study: 8418020
Drug: maxEPA 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: maxEPA 10 g/day
Study: 8418020
Drug: maxEPA 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: maxEPA 5 g/day
Study: 8418020
Drug: Placebo 20
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 g/day
Study: 3535967
Drug: Tinidazole single
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole single perioperative prophylactic dose of 2 g
Study: 3535967
Drug: Tinidazole treatment
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole treatment course of 8 g over 7 days
Study: 29058596
Drug: Inhaled Hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Hydrogen (2% hydrogen with 24% to 50% oxygen) for 18 hours after admission via mechanical ventilation
Study: 25619692
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with open reduction and internal fixation (ORIF)
Study: 14999522
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg risedronate administered in the morning under fasting condition without breakfast
Study: 14999522
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg risedronate administered 30 min before breakfast
Study: 14999522
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg risedronate administered 30 min after breakfast
Study: 14999522
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg risedronate administered 3 h after breakfast
Study: 11153450
Drug: Radical multiple
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical multiple synovectomy (RaMS) with continued pre-operative medication (group A)
Study: 11153450
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with DMARDs after RaMS (group B)
Study: 11153450
Drug: No surgery,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgery, combination therapy with DMARDs (group C - control)
Study: 3515925
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral flurbiprofen
Study: 24924800
Drug: d-cycloserine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine (250 mg)
Study: 25851453
Drug: Urea, arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea, arginine and carnosine cream (UC)
Study: 25851453
Drug: Glycerin-based emollient
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin-based emollient cream (SEC)
Study: 11074227
Drug: Citalopram (20‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20‐60 mg/day)
Study: 11074227
Drug: Sertraline (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐150 mg/day)
Study: 8823568
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (3 mg/100 ml) and 5-aminosalicylic acid (2 g/100 ml)
Study: 8823568
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (3 mg/100 ml)
Study: 8823568
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (2 g/100 ml)
Study: 1316078
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg orally once daily for 14 days)
Study: 1316078
Drug: Trimethoprim/sulfamethoxazole (TMP/SMX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily for 14 days)
Study: 1316078
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg)
Study: 28161208
Drug: Home Tablet
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Tablet (HT)
Study: 25610872
Drug: Intravaginal 1
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 1 mg prostaglandin E2
Study: 25610872
Drug: Intracervical 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical 0.5 mg prostaglandin E2
Study: 8266157
Drug: Lignocaine gel
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine gel
Study: 17655633
Drug: Water-based lubricating
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based lubricating gel
Study: 15954909
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg daily for 2 months
Study: 15954909
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg daily for 2 months
Study: 15954909
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg daily for 2 months
Study: 7763028
Drug: Pharmacokinetics monitored
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetics monitored dose adaptation of MTX (group 2)
Study: 7763028
Drug: T10 protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: T10 protocol with dose adapted only to age (group 1)
Study: 2325029
Drug: Uterine lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine lavage with 2 g of cefotaxime in 1,000 mL of normal saline
Study: 2325029
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1 g of cefotaxime after cord clamping followed by 1-g doses 6 and 12 hours later
Study: 527268
Drug: Post-operative adjuvant
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative adjuvant cyclic chemotherapy
Study: 527268
Drug: Post-operative local
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative local radiation therapy
Study: 17088141
Drug: Ciclesonide nasal
Normalized name: ciclesonide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide nasal spray (200 microg, once daily for 28 days)
Study: 26819359
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (n = 10)
Study: 11488165
Drug: LeukoNorm Cytochemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: LeukoNorm Cytochemia administered on 5 consecutive days starting with the day of oocyte retrieval (1 unit/10 kg dosage)
Study: 11488165
Drug: Normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal treatment group (non-treatment group)
Study: 8431907
Drug: Pelvic radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiation treatment
Study: 3119677
Drug: BW 942C
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW 942C (0.5 mg intravenous)
Study: 28293779
Drug: Minodronate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minodronate (50 mg/28 days)
Study: 28293779
Drug: Eldecalcitol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol (0.75 µg/day)
Study: 26639352
Drug: Eplerenone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (100 mg/dose, 2 doses, 24h between doses)
Study: 9366277
Drug: Fosinopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (ACE inhibitor)
Study: 18418363
Drug: Paroxetine (12.5-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (12.5-75 mg/day)
Study: 18418363
Drug: Venlafaxine (75-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75-375 mg/day)
Study: 30010101
Drug: Neural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural therapy (6 sessions)
Study: 26353843
Drug: Grazoprevir 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 25 mg plus PEG‐IFN/RBV
Study: 26353843
Drug: Grazoprevir 50
Normalized name: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 50 mg plus PEG‐IFN/RBV
Study: 26353843
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg plus PEG‐IFN/RBV
Study: 24433574
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (TT) patch delivering 300 mcg of testosterone/day
Study: 24433574
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (Pl)
Study: 16190388
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) 1.2 x 10(4) U/kg intravenously after induction, 0.6 x 10(4) U/kg UTI in priming solution, and 0.6 x 10(4) U/kg UTI 5 min before aortic decamping
Study: 12074692
Drug: Alteplase 100
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 100 mg (bolus) + two-stage 90 min infusion
Study: 1734364
Drug: Gentamicin otic
Normalized name: gentamicin Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin otic drops immediately after tympanostomy tube placement in the operating room only
Study: 1734364
Drug: Gentamicin otic
Normalized name: gentamicin Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin otic drops for an additional 48 hours (4 drops in each ear, three times a day)
Study: 6372437
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate 15 mg/kg twice daily for ten days
Study: 6372437
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate 25 mg/kg twice daily for ten days
Study: 30207000
Drug: Zhizhu Kuanzhong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhu Kuanzhong (ZZKZ) capsule
Study: 28846002
Drug: Parenting daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenting daily hassles and parental depressive symptoms
Study: 23494526
Drug: Booster treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster treatment
Study: 20150438
Drug: AQUA method
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQUA method of automated quantitative analysis for estrogen receptor (ER)
Study: 20150438
Drug: AQUA method
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQUA method of automated quantitative analysis for progesterone receptor (PgR)
Study: 10570376
Drug: Combined UVA-UVB
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined UVA-UVB phototherapy (minimal erythema dose dependent for 15 days)
Study: 8553408
Drug: Lubeluzole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 10 mg/d
Study: 8553408
Drug: Lubeluzole 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 20 mg/d
Study: 1846437
Drug: Unopposed conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unopposed conjugated equine estrogen (0.625 mg)
Study: 1846437
Drug: Medroxyprogesterone acetate,
Normalized name: medroxyprogesterone acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate, norethindrone acetate, or d,l-norgestrel (doses providing protection against endometrial hyperplasia)
Study: 6478427
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after initial radiotherapy
Study: 31712590
Drug: Drinking two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking two 150 ml glasses of water (Study 1 and Study 2)
Study: 24277961
Drug: Intranasal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal clonidine 4 mcg/kg
Study: 20219285
Drug: Cross-sex hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sex hormonal treatment in MF transsexuals
Study: 20219285
Drug: Cross-sex hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sex hormonal treatment in FM transsexuals
Study: 17369712
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg BW/day
Study: 17369712
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg BW/day
Study: 17369712
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg BW/day
Study: 17369712
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg BW/day
Study: 17369712
Drug: 0.7 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g/kg BW/day
Study: 17369712
Drug: >=0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: >=0.8 g/kg BW/day
Study: 9445630
Drug: Systemic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic adjuvant treatment
Study: 9445630
Drug: New cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cytotoxic agents (gemcitabine, vinorelbine, topotecan)
Study: 9445630
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with paclitaxel and docetaxel
Study: 9445630
Drug: Selective aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective aromatase inhibitors, new antigestagens, and antiestrogens
Study: 9445630
Drug: Dose intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose intensity concepts with growth factors and peripheral stem cell support
Study: 9445630
Drug: Humanized monoclonal
Normalized name: Humanized monoclonal antibody Hu1B7
DrugBank: Humanized monoclonal antibody Hu1B7 (DB17828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized monoclonal antibody against CerbB‐2 receptors